Price History

Hover for the daily close. The dotted line marks the period open.

Compare CUVL with… →

CUVL Key Statistics

As of Sep 4, 2026

Trading

Open: $6.29
Previous Close: $6.28
Day's Range: 6.10–6.73
52-Week Range: 5.95–8.92
Volume: 79.28K
Beta: 0.56

Valuation

Market Cap: $328.79M
P/E Ratio: 13.58
P/S ratio: 3.50
EPS (ttm): 0.48

Financials (FY)

Revenue (FY): $95.02M+7.76%
Net Income (FY): $36.17M+1.50%
Profit margin: 36.07%
Shares Outstanding: 50.43M
1-Year Return: −7.52%

Dividend and dates

Dividend: $0.04+0.55%
Ex-Dividend Date: September 8, 2026
Avg Volume: 9.53K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CUVL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+105.63%−30.13%−23.11%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−23.11%
2025	+10.13%
2024	−30.13%
2023	−24.75%
2022	−25.82%
2021	+17.96%
2020	−14.51%
2019	+53.48%
2018	+105.63%
2017	+18.71%
2016 (partial year)	+34.60%

As of September 4, 2026.

CUVL Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$95.02M	$36.17M	38.1%
2024	$88.18M	$35.64M	40.4%
2023	$78.32M	$30.60M	39.1%
2022	$65.72M	$20.88M	31.8%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$95.02M	$79.14M	$45.73M	$36.17M	38.1%
2024	$88.18M	$78.10M	$48.01M	$35.64M	40.4%
2023	$78.32M	$69.53M	$44.10M	$30.60M	39.1%
2022	$65.72M	$55.24M	$35.33M	$20.88M	31.8%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

CUVL Dividend History

’18’19’20’21’22’23’24

$0.03+6.3% vs 2023

Dividends per share, 2024 · 1 payments

Year	Dividends per share	Payments	Change
2024	$0.03	1	+6.3%
2023	$0.03	1	+18.5%
2022	$0.03	1	+50.0%
2021	$0.02	1	+0.0%

Year	Dividends per share	Payments	Change
2024	$0.03	1	+6.3%
2023	$0.03	1	+18.5%
2022	$0.03	1	+50.0%
2021	$0.02	1	+0.0%
2020	$0.02	1	+5.9%
2019	$0.02	1	+21.4%
2018	$0.01	1	—

Most recent payment: $0.03 per share, ex-dividend September 9, 2024. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

CUVL Valuation vs Biotechnology Median

Median of 654 stocks

Metric	CUVL	Biotechnology median	vs median
P/E	13.58	12.57	8% above
P/S ratio	3.50	15.26	0.2x the median
Profit margin	36.07%	0.00%	36.1 pts above

Medians across 654 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 7, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Clinuvel Pharmaceuticals Limited (CUVL) carries a market capitalisation of $328.79M. The company sits in the Healthcare sector, in the Biotechnology industry.

The 52-week range on file runs from $5.95 to $8.92. The most recent close on file for CUVL is $6.52, dated September 4, 2026. That is +$0.24 (+3.82%) against the previous close. The latest close sits 9.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $95.02M. Against the prior fiscal year total of $88.18M, that is a change of +7.76%. The same year closed with net income of $36.17M. That is +1.50% against the prior fiscal year. Profit margin runs at 36.07%. That is 36.1 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.48.

Across the 4 fiscal years on file, revenue moves from $65.72M in 2022 to $95.02M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

CUVL trades at a trailing price-to-earnings ratio of 13.58. That is 8.04% above the Biotechnology median of 12.57. Measured against sales, the shares trade at 3.5 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 654 Biotechnology companies that report the metric.

The reported beta is 0.56. Annualized volatility over the trailing 10 years is 53.04%. Over the trailing twelve months the price has returned −7.52%. Measured over 10 years, that is +5.11% a year compounded.

Growth & Income

The trailing dividend yield is 0.55%. That is 0.9 percentage points below the Biotechnology median yield of 1.47%. At the indicated rate that is $0.04 a share a year. The ex-dividend date on file is September 8, 2026. Dividends are recorded for 7 calendar years; 2024 shows 1 payments totalling $0.03 a share. The year before, 2023, totalled $0.03 a share.

The strongest complete calendar year on file is 2018 at +105.63%; the weakest is 2024 at −30.13%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −23.11%.

Peer Comparison

Clinuvel Pharmaceuticals Limited (CUVL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Clinuvel Pharmaceuticals Limited	CUVL	$328.79M	13.6
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	31.8
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	39.4

The Biotechnology industry average P/E ratio is 12.6x. Clinuvel Pharmaceuticals Limited trades at a P/E of 13.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Visit website →

Clinuvel Pharmaceuticals Limited (CUVL) Stock Analysis